StreetInsider.com News Articles

Form 4 Altimmune, Inc. For: Aug 13 Filed by: Durso Jerome Benedict

Thu, 13 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26920747.html

Form 4 Altimmune, Inc. For: Aug 13 Filed by: Durso Jerome Benedict

Thu, 13 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26920747.html

Form 10-Q Altimmune, Inc. For: Jun 30

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912655.html

Form 10-Q Altimmune, Inc. For: Jun 30

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912655.html

Altimmune, Inc. (ALT) Tops Q2 EPS by 3c

Wed, 12 Aug 2026 07:42:05 -0400

Altimmune, Inc. (NASDAQ: ALT) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

Form 8-K Altimmune, Inc. For: Aug 12

Wed, 12 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26908967.html

Form 8-K Altimmune, Inc. For: Aug 12

Wed, 12 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26908967.html

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Wed, 05 Aug 2026 08:00:00 -0400

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website.

Participants who would like to join the call

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Wed, 05 Aug 2026 08:00:00 -0400

Participants who would like to join the call

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Wed, 05 Aug 2026 08:00:00 -0400

Participants who would like to join the call

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Wed, 05 Aug 2026 08:00:00 -0400

Participants who would like to join the call

Form 4 Altimmune, Inc. For: Jul 31 Filed by: Roberts M Scot

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857735.html

Form 4 Altimmune, Inc. For: Jul 31 Filed by: Roberts M Scot

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857735.html

Form 4 Altimmune, Inc. For: Jul 31 Filed by: WEAVER GREGORY L

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857745.html

Form 4 Altimmune, Inc. For: Jul 31 Filed by: WEAVER GREGORY L

Mon, 03 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260803/26857745.html

Altimmune starts Phase 3 trial of pemvidutide for MASH

Mon, 03 Aug 2026 08:01:11 -0400

Altimmune, Inc. (Nasdaq: ALT) announced it has begun enrolling patients in the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled study evaluating pemvidutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis.

Pemvidutide is an investigational glucagon/GLP-1 dual receptor agonist also being studied for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The trial follows the company's IMPACT Phase 2b study and incorporates feedback from the U.S. Food and Drug Administration (FDA) and European regulatory agencies. A 52-week data readout is anticipated in 2029.

The trial includes two parallel cohorts. Cohort 1 will enroll approximately 990

Altimmune starts Phase 3 trial of pemvidutide for MASH

Mon, 03 Aug 2026 08:01:11 -0400

The trial includes two parallel cohorts. Cohort 1 will enroll approximately 990